查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1747747

全球轉錄組學技術市場

Transcriptomics Technologies
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 166 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球轉錄組技術市場規模將達到 120 億美元

全球轉錄組學技術市場規模預計在2024年為79億美元，預計到2030年將達到120億美元，2024年至2030年期間的複合年成長率為7.2%。轉錄組學耗材是本報告分析的細分市場之一，預計其複合年成長率為5.3%，到分析期結束時規模將達到47億美元。轉錄組學儀器細分市場在分析期間的複合年成長率預計為9.2%。

美國市場規模估計為 21 億美元，中國市場預計複合年成長率為 7.1%

美國轉錄組學技術市場規模預計在2024年達到21億美元。作為世界第二大經濟體，中國市場規模預計到2030年將達到19億美元，在2024-2030年的分析期間內，複合年成長率為7.1%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為6.4%和6.3%。在歐洲，預計德國市場的複合年成長率約為6.0%。

全球「轉錄組學技術」市場—主要趨勢與促進因素摘要

為什麼轉錄組學對於精準醫療時代至關重要？

轉錄組學是對基因組產生的RNA轉錄本的綜合研究，它正迅速發展成為現代生物醫學研究的基石，尤其是在日益擴張的精準醫療領域。透過分析不同組織、細胞類型和疾病狀態下基因的動態表達，轉錄組學為細胞功能和病理提供了前所未有的見解。這種能力改變了科學家診斷疾病、識別生物標記和對患者進行分層以進行標靶治療。 COVID-19大流行極大地加速了全世界對體學技術（包括轉錄組學）的認知，因為研究人員利用RNA分析來追蹤病毒進化和宿主反應。在腫瘤學領域，轉錄組分析已被廣泛用於了解腫瘤異質性和識別新的藥物標靶。此外，罕見疾病研究在轉錄組分析方面取得了突破，從而可以更好地分類和理解單表現型疾病。隨著生物製藥公司增加對個人化治療的投資，轉錄組學在藥物發現、毒理基因組學和臨床試驗最佳化中的作用正在急劇擴大。這種日益成長的臨床和商業性相關性清楚地表明了為什麼轉錄組學不再只是一種研究工具，而且擴大被視為下一代診斷和治療的基礎。

次世代定序儀和生物資訊學如何推動轉錄組學的創新？

轉錄組學的爆炸性成長得益於新一代定序 (NGS)、單細胞 RNA 定序 (scRNA-seq) 和高通量微陣列平台的技術突破。這些工具使研究人員能夠以前所未有的解析度和規模獲取基因表現數據，揭示基因活動的整體趨勢和細微變化。單細胞技術尤其徹底改變了該領域，它能夠在單一細胞層級繪製轉錄組圖，揭示先前隱藏的細胞亞型和疾病機制。同時，長讀長定序技術的進步正在解決轉錄異構體檢測和可變剪接分析的限制。然而，轉錄組學研究產生的大量資料需要先進的計算工具來管理、解釋和視覺化結果。人工智慧和機器學習模型正擴大被應用於識別複雜模式、預測基因功能和自動分類細胞類型。雲端基礎的生物資訊平台和開放原始碼資料庫正在使全球研究人員更容易使用這些強大的工具。濕實驗室創新與乾實驗室分析的結合不僅擴大了轉錄組學的效用，而且加快了多個治療領域的發現時間。

轉錄組學技術能否彌合基因組學和功能生物學之間的差距？

基因組學揭示了生命的藍圖，而轉錄組學則提供了該藍圖在各種生物和環境條件下如何被解讀的即時簡介。這種差異使得轉錄組學對於功能基因組學和系統生物學至關重要，因為在這些領域，理解基因活動的背景至關重要。例如，在免疫學中，轉錄組分析用於監測免疫細胞活化，並識別與自體免疫疾病和疫苗反應相關的細胞激素特徵。神經科學研究越來越依賴空間轉錄組學，這是一種繪製組織結構內基因表現圖譜的新方法，用於探索腦細胞多樣性和神經退化性疾病的路徑。環境轉錄組學正在幫助生態學家評估動植物對氣候變遷和污染的壓力反應。農業基因組學也受益於轉錄組學，從而能夠培育出產量更高、抗逆性和抗病蟲害的作物。此類跨學科應用反映出一種日益成長的共識，即轉錄組學彌合了靜態基因組數據與動態細胞功能之間的關鍵差距，不僅在醫療保健領域，而且在更廣泛的生命科學生態系統中都至關重要。

轉錄組學技術市場的成長受到多種因素的推動…

轉錄組學技術市場的成長受到與研究需求、技術成熟度和最終用戶擴展相關的若干因素的驅動。一個主要的催化劑是個人化醫療的興起，其中 RNA 分析在識別患者特異性疾病途徑和客製化治療方面發揮核心作用。政府和私人投資者增加對生命科學研究的資助，支持腫瘤學、感染疾病和神經生物學等領域的大規模轉錄組學研究。單細胞定序、空間轉錄組學和高通量自動化等技術進步使得能夠以更低的成本進行更廣泛、更詳細的轉錄組學分析。製藥公司正在將轉錄組學納入其藥物開發平臺，以降低化合物風險、發現脫靶效應並加快監管核准流程。臨床實驗室已開始採用轉錄組學面板作為診斷工具，尤其是在腫瘤學和罕見疾病檢測中。此外，生物資訊學平台和方便用戶使用的數據視覺化工具的廣泛普及正在使轉錄組學變得民主化，並增強了學術界和工業界研究人員的能力。法律規範也在逐步調整，以適應基於轉錄組學的診斷方法，為商業化開闢了新的途徑。這些因素共同作用，將轉錄組學從一種小眾的科學方法轉變為生物醫學和生命科學領域創新的重要引擎。

部分

類型（耗材、儀器、軟體、服務）、技術（微陣列、qPCR、定序技術）、應用（藥物研發、診斷/疾病分析、其他應用）

調查企業範例（共32家企業）

  • 10x Genomics
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company（BD）
  • Bio-Rad Laboratories, Inc.
  • BGI Genomics
  • Danaher Corporation
  • Fluidigm Corporation
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Illumina, Inc.
  • LC Sciences, LLC
  • Merck KGaA
  • NanoString Technologies, Inc.
  • PerkinElmer Inc.
  • Promega Corporation
  • Qiagen NV
  • Revvity, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vizgen, Inc.

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP35901

Global Transcriptomics Technologies Market to Reach US$12.0 Billion by 2030

The global market for Transcriptomics Technologies estimated at US$7.9 Billion in the year 2024, is expected to reach US$12.0 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Transcriptomics Consumables, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Transcriptomics Instruments segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 7.1% CAGR

The Transcriptomics Technologies market in the U.S. is estimated at US$2.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global "Transcriptomics Technologies" Market - Key Trends & Drivers Summarized

Why Is Transcriptomics Taking Center Stage in the Era of Precision Medicine?

Transcriptomics-the comprehensive study of RNA transcripts produced by the genome-has rapidly evolved into a cornerstone of modern biomedical research, especially within the expanding domain of precision medicine. By analyzing the dynamic expression of genes in different tissues, cell types, and disease states, transcriptomics offers unparalleled insights into cellular function and pathology. This capability has transformed how scientists diagnose diseases, identify biomarkers, and stratify patients for targeted therapies. The COVID-19 pandemic notably accelerated global awareness of omics technologies, including transcriptomics, as researchers used RNA profiling to track viral evolution and host responses. In oncology, transcriptome sequencing is now frequently used to understand tumor heterogeneity and identify novel drug targets. Additionally, rare disease research has seen breakthroughs through transcriptomic analysis, allowing for better classification and understanding of monogenic disorders. As biopharma companies deepen their investment in personalized therapeutics, the role of transcriptomics in drug discovery, toxicogenomics, and clinical trial optimization has expanded dramatically. This growing clinical and commercial relevance underscores why transcriptomics technologies are now regarded not just as research tools but as foundational to the next generation of diagnostics and therapeutics.

How Are Next-Gen Sequencing and Bioinformatics Powering Transcriptomics Innovation?

The explosive growth of transcriptomics owes much to technological breakthroughs in next-generation sequencing (NGS), single-cell RNA sequencing (scRNA-seq), and high-throughput microarray platforms. These tools enable researchers to capture gene expression data at unprecedented resolution and scale, revealing both broad trends and subtle variations in gene activity. Single-cell techniques, in particular, are revolutionizing the field by mapping transcriptomes at the level of individual cells, uncovering previously hidden cell subtypes and disease mechanisms. Meanwhile, advancements in long-read sequencing technologies are addressing limitations in transcript isoform detection and alternative splicing analysis. However, the deluge of data generated from transcriptomics studies requires sophisticated computational tools to manage, interpret, and visualize results. AI and machine learning models are increasingly applied to identify complex patterns, predict gene function, and automate the classification of cell types. Cloud-based bioinformatics platforms and open-source databases have made these powerful tools more accessible to researchers around the world. This integration of wet-lab innovation with dry-lab analytics is not only expanding the utility of transcriptomics but also accelerating the time-to-discovery across multiple therapeutic areas.

Can Transcriptomics Technologies Bridge the Gap Between Genomics and Functional Biology?

While genomics reveals the blueprint of life, transcriptomics provides real-time snapshots of how that blueprint is interpreted under varying biological and environmental conditions. This distinction has made transcriptomics essential for functional genomics and systems biology, where understanding gene activity in context is critical. In immunology, for example, transcriptomic profiling is being used to monitor immune cell activation and identify cytokine signatures associated with autoimmune diseases or vaccine responses. Neuroscience research is increasingly reliant on spatial transcriptomics-an emerging method that maps gene expression within tissue architecture-to explore brain cell diversity and neurodegenerative disease pathways. Environmental transcriptomics is another fast-emerging application, helping ecologists assess stress responses in plants and animals to climate change and pollution. Agricultural genomics also benefits from transcriptomics, enabling the breeding of crops with improved yield, stress tolerance, and resistance to pests. These cross-sector applications reflect a growing consensus that transcriptomics bridges the critical gap between static genomic data and dynamic cellular function, making it indispensable not just in healthcare, but across the broader life sciences ecosystem.

The Growth in the Transcriptomics Technologies Market Is Driven by Several Factors…

The growth in the transcriptomics technologies market is driven by several factors linked to research demand, technological maturity, and end-user expansion. A key catalyst is the rise of personalized medicine, where RNA profiling plays a central role in identifying patient-specific disease pathways and tailoring treatments. Increased funding for life sciences research-by both governments and private investors-is supporting large-scale transcriptomics studies in areas like oncology, infectious disease, and neurobiology. Technological advancements such as single-cell sequencing, spatial transcriptomics, and high-throughput automation are enabling broader, more detailed transcriptomic analyses at lower costs. Pharmaceutical companies are incorporating transcriptomics into drug development pipelines to de-risk compounds, understand off-target effects, and accelerate regulatory approval processes. Clinical laboratories are beginning to adopt transcriptomic panels as diagnostic tools, particularly in oncology and rare disease testing. Furthermore, the proliferation of bioinformatics platforms and user-friendly data visualization tools has democratized transcriptomics, empowering researchers in academia and industry alike. Regulatory frameworks are gradually adapting to accommodate transcriptomics-based diagnostics, opening new pathways for commercialization. Collectively, these drivers are transforming transcriptomics from a niche scientific method into a vital engine of biomedical and life science innovation.

SCOPE OF STUDY:

The report analyzes the Transcriptomics Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Consumables, Instruments, Software, Services); Technology (Microarrays, qPCR, Sequencing Technology); Application (Drug Discovery, Diagnostics & Disease Profiling, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • 10x Genomics
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • BGI Genomics
  • Danaher Corporation
  • Fluidigm Corporation
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Illumina, Inc.
  • LC Sciences, LLC
  • Merck KGaA
  • NanoString Technologies, Inc.
  • PerkinElmer Inc.
  • Promega Corporation
  • Qiagen N.V.
  • Revvity, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vizgen, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Transcriptomics Technologies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Precision Medicine and Personalized Therapy Drives Transcriptomics Adoption
    • Rapid Advances in RNA Sequencing Technologies Throw the Spotlight on Omics Integration
    • Expanding Applications in Oncology and Rare Disease Research Propel Market Growth
    • Increasing Role of Transcriptomics in Drug Discovery and Target Validation Spurs Demand
    • Expansion of Single-Cell Analysis Capabilities Accelerates Innovation and Research Outcomes
    • Collaborations Between Biotech Companies and Research Institutions Expand Commercialization Scope
    • Growing Utility of Non-Coding RNA Analysis Opens Up New Revenue Streams
    • Development of Multi-Omics Platforms Sustains Demand for High-Throughput Transcriptomics
    • Accelerating Trend Toward Predictive Diagnostics Expands the Addressable Market
    • Rising Use of Transcriptomics in Agriculture and Environmental Science Broadens Market Applications
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Transcriptomics Technologies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Transcriptomics Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostics & Disease Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Diagnostics & Disease Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Microarrays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for qPCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for qPCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • JAPAN
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • CHINA
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • EUROPE
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Transcriptomics Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • FRANCE
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • GERMANY
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • UNITED KINGDOM
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030

IV. COMPETITION